NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect
in patients with colorectal cancer. This study will also evaluate how the safety and
anti-tumor activity of NKTR-102 compares with irinotecan, a cancer drug that is approved for
use in the US for treatment of patients with certain types of colorectal cancer.